Published in Oncogene on September 25, 2006
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol (2010) 5.35
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell (2011) 4.41
Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature (2009) 4.30
A novel adaptive method for the analysis of next-generation sequencing data to detect complex trait associations with rare variants due to gene main effects and interactions. PLoS Genet (2010) 3.78
Mutation as a stress response and the regulation of evolvability. Crit Rev Biochem Mol Biol (2007) 3.66
Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46
PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A (2009) 2.98
Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol (2009) 2.88
Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol (2010) 2.07
PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res (2009) 2.01
Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth. Science (2008) 1.82
A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. J Pathol (2012) 1.67
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res (2009) 1.59
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol (2013) 1.55
PALB2 regulates recombinational repair through chromatin association and oligomerization. J Biol Chem (2009) 1.50
Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep (2009) 1.50
Functional impact of missense variants in BRCA1 predicted by supervised learning. PLoS Comput Biol (2006) 1.49
MYC in breast tumor progression. Expert Rev Anticancer Ther (2008) 1.49
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. Genes Cancer (2010) 1.48
53BP1 promotes ATM activity through direct interactions with the MRN complex. EMBO J (2009) 1.47
Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res (2009) 1.37
Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol Pharmacol (2009) 1.33
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer (2009) 1.32
Replication blocking lesions present a unique substrate for homologous recombination. EMBO J (2007) 1.29
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene (2007) 1.24
Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res (2008) 1.21
Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance. PLoS Pathog (2007) 1.18
CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics (2011) 1.17
Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem (2012) 1.17
Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. Proc Natl Acad Sci U S A (2007) 1.16
Homologous recombination conserves DNA sequence integrity throughout the cell cycle in embryonic stem cells. Stem Cells Dev (2010) 1.15
Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic. Mutat Res (2011) 1.13
The cellular response to DNA damage: a focus on MDC1 and its interacting proteins. Nucleus (2009) 1.13
The DNA damage response: Balancing the scale between cancer and ageing. Aging (Albany NY) (2010) 1.08
The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy. Cell Biosci (2013) 1.02
RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer. Carcinogenesis (2010) 1.02
Heterochromatin instability in cancer: from the Barr body to satellites and the nuclear periphery. Semin Cancer Biol (2012) 1.01
Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol (2012) 1.01
BRCA1-Ku80 protein interaction enhances end-joining fidelity of chromosomal double-strand breaks in the G1 phase of the cell cycle. J Biol Chem (2013) 1.01
Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int (2013) 1.01
Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner. Cancer Res (2009) 1.00
The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl (2012) 1.00
Timeless Maintains Genomic Stability and Suppresses Sister Chromatid Exchange during Unperturbed DNA Replication. J Biol Chem (2008) 1.00
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs (2013) 0.98
D-loop formation by Brh2 protein of Ustilago maydis. Proc Natl Acad Sci U S A (2008) 0.97
Gene-gene interactions in breast cancer susceptibility. Hum Mol Genet (2011) 0.97
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat (2012) 0.96
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum Genet (2008) 0.95
BRG1 is required for formation of senescence-associated heterochromatin foci induced by oncogenic RAS or BRCA1 loss. Mol Cell Biol (2013) 0.95
The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res (2010) 0.95
APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. EMBO J (2012) 0.94
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer (2013) 0.94
Human replication protein A-Rad52-single-stranded DNA complex: stoichiometry and evidence for strand transfer regulation by phosphorylation. Biochemistry (2009) 0.94
Common breast cancer risk variants in the post-COGS era: a comprehensive review. Breast Cancer Res (2013) 0.94
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. Mol Cancer (2008) 0.93
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer. Mol Cell Proteomics (2012) 0.93
Functional assays for analysis of variants of uncertain significance in BRCA2. Hum Mutat (2013) 0.92
Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome. PLoS One (2010) 0.92
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer (2015) 0.92
Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer. PLoS One (2011) 0.91
BRCA1 in the DNA damage response and at telomeres. Front Genet (2013) 0.91
Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med (2011) 0.90
Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins. J Cell Physiol (2009) 0.90
Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU Int (2011) 0.90
Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res (2007) 0.89
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer (2016) 0.89
The role and clinical significance of DNA damage response and repair pathways in primary brain tumors. Cell Biosci (2013) 0.89
Targeted therapy in ovarian cancer. J Oncol (2010) 0.89
EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases. Mol Genet Genomics (2011) 0.89
Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression. Breast Cancer Res (2011) 0.88
Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin. Breast Cancer (Auckl) (2009) 0.88
Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis. PLoS Genet (2010) 0.88
Mammary cancer susceptibility: human genes and rodent models. Mamm Genome (2007) 0.88
Synaptonemal complex protein SYCP3 impairs mitotic recombination by interfering with BRCA2. EMBO Rep (2011) 0.87
Update on adjuvant chemotherapy for early breast cancer. Breast Cancer (Auckl) (2014) 0.86
Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation. Future Oncol (2009) 0.86
Snm1B/Apollo functions in the Fanconi anemia pathway in response to DNA interstrand crosslinks. Hum Mol Genet (2011) 0.86
The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered Cancer Clin Pract (2015) 0.85
Drug therapy for hereditary cancers. Hered Cancer Clin Pract (2011) 0.85
Inactivating Mutations in GT198 in Familial and Early-Onset Breast and Ovarian Cancers. Genes Cancer (2013) 0.85
Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations. Biochemistry (2008) 0.84
Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours. Virchows Arch (2013) 0.84
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer (2016) 0.83
GT198 Splice Variants Display Dominant-Negative Activities and Are Induced by Inactivating Mutations. Genes Cancer (2013) 0.83
Turnover of BRCA1 involves in radiation-induced apoptosis. PLoS One (2010) 0.83
The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells. PLoS One (2013) 0.83
DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. Breast Cancer Res Treat (2015) 0.83
Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. Oncologist (2011) 0.82
The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer. J Oncol (2009) 0.82
CHEK2 1100 delC mutation in Russian ovarian cancer patients. Hered Cancer Clin Pract (2007) 0.81
Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models. Ann N Y Acad Sci (2011) 0.81
The molecular genetics of breast cancer and targeted therapy. Biologics (2007) 0.81
Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int (2015) 0.81
Hereditary breast-ovarian cancer syndrome in Russia. Acta Naturae (2010) 0.80
Molecular evolution of a Drosophila homolog of human BRCA2. Genetica (2009) 0.80
Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature. J Biol Inorg Chem (2010) 0.80
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation. BMC Cancer (2010) 0.80
BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells. Oncotarget (2012) 0.80
The product of the mouse Xist gene is a 15 kb inactive X-specific transcript containing no conserved ORF and located in the nucleus. Cell (1992) 6.26
An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science (1995) 6.03
3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol (1997) 5.66
Effect of community-based peer counsellors on exclusive breastfeeding practices in Dhaka, Bangladesh: a randomised controlled trial [see commments]. Lancet (2000) 4.67
Controlled trial of three approaches to the treatment of severe malnutrition. Lancet (1995) 4.59
Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J (1994) 4.37
BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene (2006) 3.91
Conservation of position and exclusive expression of mouse Xist from the inactive X chromosome. Nature (1991) 3.43
Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J (2001) 3.21
BRCA2 mutations in primary breast and ovarian cancers. Nat Genet (1996) 2.91
Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Methods Enzymol (1995) 2.82
Xist has properties of the X-chromosome inactivation centre. Nature (1997) 2.78
An SRY-related gene expressed during spermatogenesis in the mouse encodes a sequence-specific DNA-binding protein. EMBO J (1992) 2.56
Isolation and sequence of a human cytochrome P-450 cDNA clone. Proc Natl Acad Sci U S A (1985) 2.42
Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet (1997) 2.41
Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol (2006) 2.40
Why have mortality rates for severe malnutrition remained so high? Bull World Health Organ (1996) 2.39
Expression of Xist during mouse development suggests a role in the initiation of X chromosome inactivation. Cell (1993) 2.30
A conserved family of genes related to the testis determining gene, SRY. Nucleic Acids Res (1992) 2.26
Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr Biol (1999) 2.17
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene (2010) 2.11
The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases. J Biol Chem (1996) 2.04
Measuring hygiene practices: a comparison of questionnaires with direct observations in rural Zaïre. Trop Med Int Health (1997) 1.99
Identification of six Tcp-1-related genes encoding divergent subunits of the TCP-1-containing chaperonin. Curr Biol (1994) 1.87
Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol Cell Biol (1999) 1.77
Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol (2005) 1.67
A short pseudoautosomal region in laboratory mice. Genome Res (2001) 1.64
Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol (2006) 1.63
Growth rates in children recovering from protein-calorie malnutrition. Br J Nutr (1969) 1.62
The BRC repeats are conserved in mammalian BRCA2 proteins. Hum Mol Genet (1997) 1.62
The Sry-related HMG box-containing gene Sox6 is expressed in the adult testis and developing nervous system of the mouse. Nucleic Acids Res (1995) 1.61
Interventions for the control of diarrhoeal diseases among young children: weaning education. Bull World Health Organ (1985) 1.59
Potential interventions for the prevention of childhood pneumonia in developing countries: improving nutrition. Am J Clin Nutr (1999) 1.57
EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol (2006) 1.57
Transgenic mice carrying an Xist-containing YAC. Hum Mol Genet (1996) 1.56
MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases. Oncogene (1999) 1.55
DNA binding and bending properties of the post-meiotically expressed Sry-related protein Sox-5. Nucleic Acids Res (1994) 1.54
Endo180, an endocytic recycling glycoprotein related to the macrophage mannose receptor is expressed on fibroblasts, endothelial cells and macrophages and functions as a lectin receptor. J Cell Sci (2000) 1.50
LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers syndrome kinase LKB1. Hum Mol Genet (2001) 1.47
Evolutionary rate of a gene affected by chromosomal position. Curr Biol (1999) 1.47
HEX: a novel homeobox gene expressed during haematopoiesis and conserved between mouse and human. Nucleic Acids Res (1993) 1.38
Evaluating the clinical management of severely malnourished children--a study of two rural district hospitals. S Afr Med J (2001) 1.37
The mitogen-activated protein kinase phosphatase-3 N-terminal noncatalytic region is responsible for tight substrate binding and enzymatic specificity. J Biol Chem (1998) 1.37
A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol (2007) 1.36
A contravention of Ohno's law in mice. Nat Genet (1995) 1.34
Faltering in infant growth in less-developed countries. Lancet (1980) 1.34
Calorie requirements of children recovering from protein-calorie manutrition. Lancet (1968) 1.31
Community-based hygiene education to reduce diarrhoeal disease in rural Zaire: impact of the intervention on diarrhoeal morbidity. Int J Epidemiol (1994) 1.31
Infant mortality in developing countries. Arch Dis Child (1982) 1.30
New complexities for BRCA1 and BRCA2. Curr Biol (2001) 1.30
Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer (2009) 1.30
Metabolic rates during recovery from protein-calorie malnutrition: the need for a new concept of specific dynamic action. Nature (1969) 1.30
Microarray and histopathological analysis of tumours: the future and the past? Nat Rev Cancer (2001) 1.28
Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4. J Biol Chem (1997) 1.27
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene (2007) 1.27
The mouse Peutz-Jeghers syndrome gene Lkb1 encodes a nuclear protein kinase. Hum Mol Genet (1999) 1.22
Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol (2008) 1.21
Molecular profiling of breast cancer: clinical implications. Br J Cancer (2004) 1.19
A candidate spermatogenesis gene on the mouse Y chromosome is homologous to ubiquitin-activating enzyme E1. Nature (1991) 1.18
Catch-up growth in children. Nutr Rev (1986) 1.17
Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res (1997) 1.17
The Y* rearrangement in mice: new insights into a perplexing PAR. Cytogenet Cell Genet (1998) 1.16
The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol (2008) 1.14
Functions of the BRCA1 and BRCA2 genes. Curr Opin Genet Dev (1998) 1.13
Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol (2008) 1.13
Cloning and characterization of SOX5, a new member of the human SOX gene family. Genomics (1996) 1.12
Influence of demographic, socioeconomic and environmental variables on childhood diarrhoea in a rural area of Zaire. J Trop Med Hyg (1994) 1.12
Management of protein-energy malnutrition in Nigeria: an evaluation of the regimen at the Kersey Nutrition Rehabilitation Centre, Nigeria. Trans R Soc Trop Med Hyg (1995) 1.11
Cloning and sequencing of POU-boxes expressed in mouse testis. Nucleic Acids Res (1990) 1.09
The Breakthrough Generations Study: design of a long-term UK cohort study to investigate breast cancer aetiology. Br J Cancer (2011) 1.09
Prevalence of anemia in children 6-59 months old in the state of Pernambuco, Brazil. Rev Panam Salud Publica (2001) 1.08
Expression of sox11 gene duplicates in zebrafish suggests the reciprocal loss of ancestral gene expression patterns in development. Dev Dyn (2000) 1.08
Effect of zinc supplementation on the morbidity, immune function, and growth of low-birth-weight, full-term infants in northeast Brazil. Am J Clin Nutr (1998) 1.07
Breast-feeding among the urban poor in southern Brazil: reasons for termination in the first 6 months of life. Bull World Health Organ (1989) 1.07
Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene (2009) 1.07
Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer (2010) 1.06
Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours. Oncogene (2011) 1.06
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol (2013) 1.06
The proteasome is involved in determining differential utilization of double-strand break repair pathways. Oncogene (2007) 1.06
Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J Pathol (2007) 1.04
Infant mortality in southern Brazil: a population based study of causes of death. Arch Dis Child (1987) 1.02
Cloning, chromosomal mapping and expression pattern of the mouse Brca2 gene. Hum Mol Genet (1997) 1.02
Growth, morbidity, and mortality of children in Dhaka after treatment for severe malnutrition: a prospective study. Am J Clin Nutr (1998) 1.02
Low birth weight and morbidity from diarrhea and respiratory infection in northeast Brazil. J Pediatr (1996) 1.01
Interventions for the control of diarrhoeal diseases among young children: prevention of low birth weight. Bull World Health Organ (1985) 1.00
Lung function and exercise performance of healthy Caribbean men and women of African ethnic origin. Q J Exp Physiol Cogn Med Sci (1972) 1.00
Complementation of byr1 in fission yeast by mammalian MAP kinase kinase requires coexpression of Raf kinase. Nature (1993) 0.99
Breastfeeding and early weaning practices in northeast Brazil: a longitudinal study. Pediatrics (2001) 0.99
A zinc finger protein-encoding gene expressed in the post-meiotic phase of spermatogenesis. Gene (1991) 0.98
Determinants of age at menarche in the UK: analyses from the Breakthrough Generations Study. Br J Cancer (2010) 0.98
Isolation and characterisation of a uniquely regulated threonine, tyrosine phosphatase (TYP 1) which inactivates ERK2 and p54jnk. Oncogene (1995) 0.98
Cloning, chromosomal localization and expression pattern of the POU domain gene Oct-11. Nucleic Acids Res (1993) 0.97
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer (2006) 0.97
The threonine residues in MAP kinase kinase 1 phosphorylated by MAP kinase in vitro are also phosphorylated in nerve growth factor-stimulated rat phaeochromocytoma (PC12) cells. FEBS Lett (1994) 0.97
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer (2014) 0.96
A gene spans the pseudoautosomal boundary in mice. Proc Natl Acad Sci U S A (1997) 0.96
Structural variation of the pseudoautosomal region between and within inbred mouse strains. Proc Natl Acad Sci U S A (1996) 0.95
The ZFY gene family in humans and mice. Trends Genet (1991) 0.94
Ad lib. feeding during recovery from malnutrition. Br J Nutr (1974) 0.93